Table 1.
Results of Prospective Clinical Trials for Infants and Young Children with Ependymoma
| Event Free Survival | Overall Survival | References | ||||
|---|---|---|---|---|---|---|
| Trial | N | Age (mo) | 1 year | 5 years (unless otherwise specified) | 5 years (unless otherwise specified) | |
| CCG 8-in-1 | 15 | 22 (3) | 8 | |||
| HIT 88/89/91 | 55 | 75.6 (3) | 24 | |||
| GTR | 28 | |||||
| STR | 27 | |||||
| Baby POG 8633 | 48 | <36 | 25 | 40.5 | 25 | |
| GTR | 23 | 66 | ||||
| 8 | 0–24 | 87 | 25.7 | 37.5 | ||
| 8 | 24–36 | 94 | 63.3 | 87.5 | ||
| STR | 25 | 25 | ||||
| SFOP | 73 | 22 (4) | 59 (4) | 26 | ||
| GTR | 74 (4) | |||||
| STR | 35 (4) | |||||
| VETOPEC | 14 | 36 (3) | 27 | |||
| CCG 9921 | 74 | 72 | 32 | 59 | 12 | |
| M0 with min residual | 42 | 79 | 33 | 67 | ||
| 20 | 75 | 29 | 54 | |||
| M0, other | 12 | 42 | 33 | 40 | ||
| M1+ | ||||||
| MD Anderson | 5 | 40 (>5) | 28 | |||
| Head Start I/II | 29 | 12 | 38 | 29 | ||
| GTR | 18 | 42 | ||||
| STR | 11 | 31 | ||||